Merck, a leading science and technology company, has introduced Viresolve® Barrier capsule filters to reduce the risk of bioreactor contamination.

Viresolve® Barrier filters are designed to remove viruses, mycoplasma and bacteria from cell culture media.

Viresolve® Barrier filters are a key component of Merck’s Viral Safety Assurance Program to mitigate the risk of viral contamination in upstream bioprocesses and minimizes the potential impact on drug supply and patient safety.

The Viral Safety Assurance Program takes a holistic approach to viral safety, offering solutions to prevent viruses from entering upstream processes detect viruses in cells, raw materials and process intermediates and remove viruses in downstream processes. 

Scalable from bench through commercial manufacturing, Viresolve® Barrier filters offer high flux and high capacity virus filtration to ensure productivity, without impacting cell culture performance or protein quality attributes.

These capsule filters are easy to implement directly in front of the bioreactor or into a media storage container. 

The company’s process solution business zone provides the industry’s most comprehensive portfolio of high quality products and services for biopharmaceutical manufacturing.